GSK lung drug succeeds in big UK study, after earlier miss

LONDON, May 24 (Reuters) - GlaxoSmithKline's new inhaled medicine Breo proved significantly better than standard care in a large British study that tested it in everyday use, providing a fillip for the product after the failure of another big trial in 2015.